Published in Pharma Investments, Ventures and Law Weekly, March 20th, 2005
The net loss on a GAAP basis for the quarter was $9.0 million or $0.10 per share as compared to a net loss of $20.9 million or $0.23 per share for the same period in 2003. The decrease in the net loss for the quarter ended December 31, 2004, as compared to the same period in 2003 was primarily the result of an increase in revenues related to Risperdal Consta.
Total manufacturing and royalty revenues from Risperdal Consta increased 67% over the last quarter, from $9.9 million in the quarter ended September 30, 2004, to $16.6 million in this quarter...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.